Ipamorelin: the selective GH pulse, and the stack it gets paired with.

The short version

Ipamorelin is a small lab-made peptide (a short chain of five amino acids) that tells the pituitary gland to release a pulse of growth hormone. What set it apart when it was first described is selectivity: it pushes growth hormone up without also pushing up cortisol (a stress hormone) or prolactin, which the older peptides in its family did ^[1]. It has never been approved as a medicine anywhere, and the one human trial that tested it for a real condition did not work ^[3].

Most people searching for it online are really searching for a pair: ipamorelin plus CJC-1295. These are two different peptides that hit growth hormone through two different doors, which is the reason they get combined. The honest catch is that the pair itself has never been tested as a finished product in a controlled trial — the case for it is built from each peptide studied on its own ^[13][17]. This site reads the actual studies, keeps the single-peptide findings separate from the combination claims, and is upfront about what people report — including the downsides — on the effects page.

What the ipamorelin literature actually measured

In its founding 1998 characterization, ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) released growth hormone potently in rat pituitary cells, anaesthetized rats, and conscious swine — a swine ED50 of 2.3 nmol/kg, against 3.9 nmol/kg for the older peptide GHRP-6 ^[1]. The defining result was what it did not do: even at doses more than 200 times its growth-hormone ED50, it did not raise ACTH (the signal that drives cortisol) or cortisol above the level seen with GHRH ^[1]. That selectivity is the entire reason ipamorelin exists as a distinct compound.

The human dataset is thin and old. Population pharmacokinetic modeling in healthy male volunteers (n=8 per dose, five 15-minute IV infusions from 4.21 to 140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of roughly 2 hours, and a single discrete growth-hormone pulse peaking about 40 minutes after dosing ^[2]. Those are the numbers — a clean pulse, a short half-life, linear kinetics.

In rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms/day (split three times daily for 15 days) raised longitudinal bone growth from 42 to 44, 50, and 52 micrometers/day in a dose-dependent way — with no measurable change in total IGF-1 ^[4]. The skeletal effect tracked the dose; the systemic IGF-1 marker did not move.

Why ipamorelin is studied as part of a stack

Ipamorelin works on the ghrelin receptor (GHS-R1a — the same receptor the hunger hormone ghrelin uses). A GHRH analog like CJC-1295 works on a different receptor entirely. Two doors, one room: combining a pulsatile ghrelin-receptor peptide with a steady GHRH-pathway peptide is the published rationale for the popular ipamorelin cjc-1295 pairing.

The class-level human evidence for that synergy is real but is about other peptides in the same families. Co-administering hexarelin (a GHRP) with GHRH produced peak growth-hormone secretion significantly greater than the arithmetic sum of each alone — true synergism, p=0.001 — in healthy men ^[8]. A 30-day continuous infusion of GHRP-2 plus GHRH drove greater growth-hormone output than either agent alone in older adults, with sustained IGF-1 and no tachyphylaxis ^[7]. CJC-1295 itself, the usual partner, produced 2- to 10-fold growth-hormone increases for six-plus days after a single subcutaneous dose in healthy adults ^[13]. None of those trials used ipamorelin; they establish the class principle, not a tested ipamorelin product. See how the comparison runs against the GHRH analogs on ipamorelin vs sermorelin.

What this site is, and what it is not

Ipamorelin Meds is an independent editorial digest. It reads the published ipamorelin literature, charts the comparable numbers, and keeps a hard line between what a study measured and what a forum claims. It is not a clinic, it does not provide medical advice, and it does not sell anything.

The through-line of every page is the same discipline a dashboard imposes: a figure is only as good as its source. Monotherapy findings are labeled as monotherapy. Combination claims are labeled as combination claims and tied to the single-agent pharmacology they actually rest on. The failed human trial ^[3] and the absent long-term safety record are stated plainly, not buried. Start with Ipamorelin research, then weigh Ipamorelin effects, and check every figure against Ipamorelin references.